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Protein Kinase D isoforms (PKD 1-3) are key mediators of neurohormonal, oxidative, and
metabolic stress signals. PKDs impact a wide variety of signaling pathways and cellular
functions including actin dynamics, vesicle trafficking, cell motility, survival, contractility,
energy substrate utilization, and gene transcription. PKD activity is also increasingly
linked to cancer, immune regulation, pain modulation, memory, angiogenesis, and
cardiovascular disease. This increasing complexity and diversity of PKD function,
highlights the importance of tight spatiotemporal control of the kinase via protein–
protein interactions, post-translational modifications or targeting via scaffolding proteins.
In this review, we focus on the spatiotemporal regulation and effects of PKD signaling
in response to neurohormonal, oxidant and metabolic signals that have implications for
myocardial disease. Precise targeting of these mechanisms will be crucial in the design
of PKD-based therapeutic strategies.
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INTRODUCTION
Protein kinase D (PKD) is emerging as a key signaling hub in the heart affecting excitation-
contraction coupling, gene expression, cell survival, and metabolism (Figure 1). There is
compelling evidence from numerous in vitro and in vivo studies for a prominent PKD
role in activating gene programs driving adverse morphological and functional changes in
cardiomyopathy, prompting considerable excitement in its therapeutic potential. In vivo, cardiac-
specific expression of constitutively active PKD1 caused pronounced dilated cardiomyopathy; and
PKD expression and activity is increased in failing mouse, rat, rabbit and human myocardium
vs. non-failing (Harrison et al., 2006; Bossuyt et al., 2008; Taglieri et al., 2014). Genetic studies
including genome wide association studies also linked mutations in the PRKD1 gene to syndromic
congenital heart defects and body mass index (an established risk factor for cardiovascular disease;
Speliotes et al., 2010; Comuzzie et al., 2012; Graff et al., 2013; Shaheen et al., 2015; Sifrim
et al., 2016). In loss-of-function studies, cardiac-specific PKD1 knockout mice (cKO) proved
remarkably resistant to cardiac hypertrophy and fibrosis in response to pressure overload or
chronic administration of both isoproterenol and angiotensin (Fielitz et al., 2008). Interestingly,
beneficial effects of PKD were also found recently. PKD activation enhanced tolerance to
ischemia/reperfusion injury (Xiang et al., 2011, 2013b). PKD activation also mitigated lipid
accumulation, insulin resistance and maladaptive remodeling in diabetic cardiomyopathy (Dirkx
et al., 2014) although other groups found PKD inhibition enhanced cardiac function in that setting
(Liu et al., 2015; Venardos et al., 2015). These observations underscore the need for better insight
into the mechanistic basis of PKD actions in the heart and their role in cardiovascular disease.
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FIGURE 1 | Microdomain Functions of Protein Kinase D (PKD). Spatial regulation of PKD activity allows for specificity of PKD function. PKD localizes to the
membrane after Gαq signaling initiates DAG production via phospholipase C. There PKD phosphorylation of Rem1 results in greater membrane insertion and activity
of L-type Ca2+ channels (LTCC). PKD targeting to the myofilaments and its substrates, TnI and MyBPC, results in decreased myofilament Ca2+ sensitivity, increased
cross bridge cycling rate, and increased contraction tension. Nuclear localization and exclusion sequences within PKD regulate nuclear localization potentially along
with the chaperone protein Hsp20. PKD regulates growth through phosphorylation of HDAC5 and CREB. In non-cardiovascular cell types, PKD is linked to Golgi
organization, membrane-vesicle fusion, and secretion. In the heart, vesicle trafficking is potentially linked to increased glucose uptake during pacing through GLUT4
membrane translocation. Of the actin remodeling effects described for PKD, only the Slingshot 1L (SSH1L)-cofilin signaling axis has been demonstrated in myocytes
and linked to cell survival. PKD-IKKβ signaling has also been linked to cell survival and reactive oxygen species (ROS) clearance. Dashed arrows indicate pathways
or functions not shown in cardiovascular cell types.
PKD STRUCTURE AND ACTIVATION
MECHANISMS
There are three highly homologous PKD isoforms: PKD1/PKCµ,
PKD2, and PKD3/PKCν (Valverde et al., 1994; Hayashi et al.,
1999; Sturany et al., 2001). Of these, PKD1 is the most
studied in cardiomyocytes. While the PKD isoforms have a
similar modular structure, they do exhibit some variability
which may account for some of the distinct functions of PKD
isoforms that are emerging (Ellwanger and Hausser, 2013).
PKDs consist of a highly conserved C-terminal catalytic domain
(consisting of motifs required for ATP/substrate-binding and
catalysis) and an N-terminal regulatory domain (Figure 2). The
structural and enzymatic properties of the catalytic domains are
quite distinct from those of the protein kinase A, G, and C
(AGC) serine/threonine kinase subfamily (Hanks, 2003). Thus
PKD isoforms have been reassigned to the Ca2+/calmodulin-
dependent protein kinase (CaMK) superfamily.
The autoinhibitory N-terminal domain contains twin
cysteine-rich zinc-finger motifs (C1a and C1b) and a pleckstrin
homology (PH) domain. The tandem C1 motifs function as
lipid-binding membrane-targeting modules without a calcium
requirement (similar to their counterparts in PKCs). The
differential lipid-binding preferences of the individual motifs
result in their different roles in intracellular targeting of PKD,
although non-lipid-binding interactions contribute too (e.g.,
with the nuclear localization signal in C1b; Rey et al., 2001a;
Oancea et al., 2003; Wang et al., 2003; Chen et al., 2008). The
C1 motifs also modulate kinase activity, however, the extent of
catalytic inhibition depends upon the isoform. In PKD1, deletion
of C1a, C1b or both results in constitutive activity; whereas in
PKD2, little to no effect on PKD activity is seen with C1 deletion
(Iglesias and Rozengurt, 1999; Auer et al., 2005).
The PH domain likewise suppresses catalytic activity, an effect
which is relieved by tyrosine phosphorylation within the PH
domain (Storz et al., 2003), protein interactions with the PH
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FIGURE 2 | Oxidative stress regulation of PKD mediated anti-apoptotic
signaling. PKD both regulates and is regulated by apoptotic signals. (A) In
response to ischemia reperfusion injury, cardiac myocytes release of
sphingosine 1 phosphate which acts through Gα12/13-coupled receptors to
activate RhoA. Rho A mediates PKC and PKD activation through activation of
phospholipase Cε. PKD phosphorylation of the phosphatase slingshot 1 L
(SSH1L) inhibits the ability of SSH1L to activate cofilin, preventing it from
translocating with Bax to the mitochondria. (B) Generation of mitochondrial
ROS results in DAG production through phospholipase D1 and PKD
localization at the mitochondria. Once at the mitochondria, c-Abl and Src
phosphorylation of PKD allows for PKCδ activation of PKD. Active PKD goes
on to phosphorylate IκBα resulting in NFκB gene transcription of MnSOD,
which allows for greater mitochondrial clearance of ROS. (C) Increased
oxidative stress through H2O2 treatment causes PKD translocation to the
nucleus and results in 14-3-3 interaction with two phosphorylated serine pairs
in the linker region between the C1 domains of PKD. Apoptosis
signal-regulating kinase 1 (ASK1) associates with the PH domain of PKD1,
leading to ASK1 activation of c-Jun N-terminal kinase (JNK); and
JNK-mediated apoptosis in endothelial cells.
domain (e.g., with PKCη or Gβγ (Jamora et al., 1999; Waldron
et al., 1999) and/or by activation loop phosphorylation (Waldron
and Rozengurt, 2003). The PH domain also contains a nuclear
export signal for PKD in the Crm1-dependent nuclear export
pathway (Rey et al., 2001a; Auer et al., 2005) but unlike other
PH domains, it displays only low affinity toward phospholipids
(Wang et al., 2003). It is still unclear whether the PH domain
contributes to the membrane-docking interactions of PKD.
Finally, the C-terminal autophosphorylation sites in PKD1
and 2 are part of a post-synaptic density-95/discs large/zonula
occludens-1 (PDZ) binding motif, which is absent in PKD3
(Sanchez-Ruiloba et al., 2006). This raises the possibility of
isoform-specific and phosphorylation-dependent interactions
with PDZ proteins (Rybin et al., 2009) and might constitute
a more common mechanism to activate a select subset of
kinase targets. For instance the PDZ scaffold protein NHERF1
[linked to the trafficking of ion transporters, receptor tyrosine
kinases and G protein coupled receptors (GPCRs)], was shown
to interact specifically with PKD1 and 2 (Kunkel et al., 2009).
Interestingly, NHERF1 association was capable of influencing
the spatiotemporal dynamics of PKD signaling. In NHERF1-
expressing HeLa cells, histamine-induced PKD1 activation at
NHERF1 scaffolds is faster, more sustained, and smaller in
magnitude than cytosolic PKD1 activation. The functional
relevance of the PDZ-motif dependent regulation of PKD
signaling has yet to be considered in cardiovascular tissues.
The structural modules of PKDs are intricately linked to
the complex regulation of PKD activity and diversity of PKD
actions. A wide array of stimuli can activate PKD including
GPCR agonists, growth factors and cytokines (Rozengurt et al.,
2005; Steinberg, 2012). In the classical activation mechanism, first
described by the Rozengurt group, PKD is relieved from its basal
autoinhibited state as follows: receptor stimulation promotes
DAG accumulation, directly activating and colocalizing PKD at
lipid membranes with allosterically activated PKCs. PKCs then
trans-phosphorylate PKD at two highly conserved serine residues
in the activation loop of the catalytic domain (S744 and S748
in mouse PKD1), relieving autoinhibition by the PH domain.
PKD then autophosphorylates a cluster of sites in the C1a-
C1b interdomain region and at S916 at the extreme C-terminus
(mouse PKD1 nomenclature; not present in PKD3), resulting
in altered binding partners and localization within the cell. The
calcium-independent, novel PKCs (nPKCs: δ, ε, η, and θ) are the
dominant PKCs involved in this process (Rey et al., 2001b, 2004;
Brandlin et al., 2002; Yuan et al., 2002; Waldron and Rozengurt,
2003). However, in endothelial cells, calcium-dependent PKCα
plays a role in vascular endothelial growth factor (VEGF)-
induced PKD activation (Wong and Jin, 2005). Of note, PKCδ
and ε have been linked to cardiomyocyte hypertrophy and death
(Dorn and Force, 2005). PKC activity may also facilitate PKD
“release” from the membrane (Rey et al., 2001b). The membrane
translocation of PKD and subsequent redistribution to different
subcellular compartments is considered a hallmark of PKD
activation and has been used as a surrogate marker of enzyme
activation in a cellular context (similar to PKCs).
This simple model of PKD activation is insufficient to explain
the spatiotemporal dynamics of PKD activity in all cell types
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or even in response to all GPCRs. More recent studies indicate
additional auto- and trans-phosphorylation reactions (by PKC
and other kinases) and other regulatory mechanisms (e.g.,
proteolytic cleavage and docking interactions) can influence
PKD signaling efficiency and specificity (reviewed in Steinberg,
2012). The functional impact of phosphorylation patterns also
appears more complex. For instance, under prolonged Gαq
activity each residue of the PKD activation loop is regulated by
different mechanisms, namely transphosphorylation for S744 and
autophosphorylation for S748 (Jacamo et al., 2008; Sinnett-Smith
et al., 2009; Waldron et al., 2012). Likewise S916 phosphorylation
has often been used as a marker of PKD activation, however,
under some conditions it may be phosphorylated after PKD
inactivation, or remain unphosphorylated while the kinase is
active (Storz et al., 2004; Sanchez-Ruiloba et al., 2006; Rybin
et al., 2009; Qiu et al., 2014). Additionally, both S916 and the
activation loop phosphorylation were found after treatment with
PKD inhibitors such as CID and Gö 6976. These phosphorylation
events are uncoupled from PKD activation, as both inhibitors
effectively prevent PKD catalytic activity (Kunkel and Newton,
2015). Thus, the activation loop or S916 phosphorylation state is
not always equivalent to kinase activity and should not be used as
the sole readout of PKD activation.
Interestingly, while the regulatory role of phosphorylations
has been extensively studied, to date the effect of other post-
translational modifications on PKD function has not been
assessed. Moreover only a fraction of PKD-activating signaling
pathways, PKD substrates and functions have been validated
in cardiomyocytes (Table 1). Putative PKD substrates generally
conform to the (L/V/I)X(R/K)XX(S/T) target motif which favors
an aliphatic amino acid at the−5 position and a basic amino acid
at the −3 position (Nishikawa et al., 1997; Franz-Wachtel et al.,
2012). While some key cardiac PKD targets have been identified
(e.g., class IIa histone deacetylases (HDACs) and troponin I)
(Figure 1), it remains unknown to what extent the related
CaMKII and PKD share effector targets {such as ion channels,
Ca2+ handling proteins [phospholamban (PLB), ryanodine
receptor (RyR)]}. Elucidation of the molecular mechanisms of
PKD regulation, its effectors and their functional relevance in the
healthy and diseased heart are major challenges to be met.
NEUROHORMONAL
STRESS-DEPENDENT PKD SIGNALING
Neurohumoral adaptations in response to cardiac stress, initially
compensating, ultimately fuel maladaptive cardiac remodeling
and deteriorating cardiac performance (Bisping et al., 2014;
Spaich et al., 2015; Tham et al., 2015). PKD signaling has
been linked to virtually all basic cellular processes involved
in remodeling, such as hypertrophy, cell death, fibrosis,
angiogenesis, and inflammation. The neurohumoral storm
mediators (mainly endothelin, angiotensin, and catecholamines)
are all known triggers of spatial and temporal shifts in PKD
activity. In cardiomyocytes, Gq-coupled GPCRs activate PKD
isoforms via phospholipase Cβ production of DAG and PKC but
stimulus-specific differences exist. For example, PKD1 activity
following α1-adrenergic receptor (α1-AR) stimulation is entirely
PKC-dependent, whereas only the initial phase of endothelin
(ET)-triggered PKD activity requires PKC (Haworth et al., 2000;
Vega et al., 2004; Guo et al., 2011). The spatiotemporal dynamics
of PKD activation also differ in adult cardiomyocytes: although
phenylephrine (PE, an α1-AR agonist) and ET trigger comparable
global PKD activation, PE induces transient sarcolemmal PKD
recruitment and activation followed by nuclear import and
ET prompts persistent sarcolemmal translocation and activity
(Bossuyt et al., 2011). The PKD isoforms are also activated
in an agonist-specific manner: norepinephrine (NE, an α/β-AR
agonist) selectively activates PKD1 in neonatal myocytes and
cardiac fibroblasts, whereas ET, thrombin and platelet derived
growth factor (PDGF) favor PKD2/3 activation (Guo et al., 2011;
Qiu and Steinberg, 2016). The molecular mechanisms underlying
the differences between these two seemingly similar Gq-coupled
receptors (GqR) remain to be identified.
Initial reports regarding β-AR modulation of PKD signaling
were conflicting. The Olson group saw no effect of β-AR or
PKA stimulation of PKD phosphorylation or activity (Harrison
et al., 2006). In contrast, A kinase anchoring protein (AKAP)-
Lbc was found to function as a scaffold for PKA and PKC,
facilitating PKD1 activation and the transduction of hypertrophic
responses (Carnegie et al., 2004, 2008). Conversely, others
examining global PKD1 activity reported suppression of PKD
activity by β-AR agonists or PKA (Haworth et al., 2011; Sucharov
et al., 2011). Some of these conflicting reports likely reflect
that global PKD1 measurements do not necessarily capture
discrete pools of PKD1 signaling (Qiu and Steinberg, 2016).
Indeed, specific examination of PKD microdomain signaling
revealed β-AR signaling triggers both local nuclear signaling
and inhibits GqR-mediated PKD1 activation by preventing its
intracellular translocation (Nichols et al., 2014). Fine-tuning PKD
responsiveness to GqR-agonists occurred via PKA-dependent
phosphorylation of PKD S427. In this regard PKD S427 serves
as an integration point of β-AR and GqR stimuli, which could be
particularly relevant in heart failure progression where the β-AR
pathway is desensitized.
The profibrotic mineralocorticoid aldosterone and
angiotensin also activate PKD1 signaling in cardiomyocytes,
suggesting a role for PKD in the control of cardiac fibrosis
(Tsybouleva et al., 2004; Iwata et al., 2005). PKD1 cKO mice
were dramatically resistant to fibrosis (Fielitz et al., 2008).
Growing evidence from the cancer field also implicate PKD in
cell proliferation and extracellular matrix remodeling via control
of matrix metalloproteinase (MMP) expression and activity (Ha
et al., 2008; Eiseler et al., 2009; Biswas et al., 2010; Yoo et al., 2011;
Durand et al., 2016). PKD also promotes aldosterone production
in adrenal cells, introducing the possibility that PKD contributes
to a positive feedback loop that promotes fibrosis (Romero et al.,
2006; Chang et al., 2007; Shapiro et al., 2010; Olala et al., 2014).
Neurohormonal Regulation of Plasma
Membrane Signaling
At the sarcolemma, enigma homolog 1 scaffolds PKD1 to increase
Ca2+ current of voltage-gated Ca2+ channels in response to
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TABLE 1 | Protein Kinase D target phosphorylation sites and verified functions in cardiovascular cell types.
Target Phosho-site Function Agonist/Model Cell/tissue type Species Source
Rem1 S18 Increased LTCC trafficking
to the membrane and
activity
Phenylephrine Neonatal and adult
ventricular myocytes
Rat Jhun et al., 2012
eNOS S1179 Increased NO synthesis VEGF, PDBu Aortic endothelial cells Cattle Aicart-Ramos et al., 2014
HDAC5 S259, S498 Nuclear export and MEF2
upregulation
PE, ET-1, Fetal Bovine
Serum
Neonatal and adult
ventricular myocytes
Rabbit Vega et al., 2004; Bossuyt
et al., 2008
CREB S133 Increased Bcl2 expression Thrombin and P. multocida
toxin (rat), Gαq
overexpression (mouse)
Neonatal ventricular
myocytes and fibroblasts
(rat), adult whole ventricle
(mouse)
Rat, Mouse Ozgen et al., 2008
Telethonin S157, S161 Maintenance of T-tubule
organization and calcium
transient dynamics
Constitutively
phosphorylated
endogenously/In vitro
kinase assay, Adenovirus
expression
Adult ventricular myocytes,
whole heart
Rat Candasamy et al., 2014
Tn I S22, S23 Reduction of myofilament
calcium sensitivity
ET-1 Intact and skinned adult
ventricular myocytes
Rat Cuello et al., 2007
MyBPc S302 Acceleration of
cross-bridge kinetics
±PKD Skinned ventricular
myocytes
Mouse Bardswell et al., 2010
MyBPc S315 Increase in maximal
calcium-activated
contraction tension
WT/cMyBPc KO myocytes
±PKD
Permeabilized adult
ventricular myocytes
Rat Dirkx et al., 2012a
SSH1L S978 Protection from oxidative
stress response of Cofilin 2
Sphingosine 1-phosphate Cardiomyocytes and whole
left ventricles
Mouse Xiang et al., 2013b
α1-AR but not β-AR stimulation (Maturana et al., 2008). PKD
phosphorylation of Serine 1884 in the L-type Ca2+ channel
(LTCC) results in increased open probability of the channel (Aita
et al., 2011). PKD1 also regulates LTCC trafficking and function
indirectly via phosphorylation of the GTP-binding protein
Rem1 (for Rad and Gem-related) at S18. This relieves Rem1
inhibition of LTCCs, resulting in greater T-tubule expression and
a corresponding increase in Ca2+ current density (Jhun et al.,
2012).
Protein Kinase D1 has also been implicated in the
phosphorylation and regulation of constitutive nitric oxide
synthases (endothelial and neuronal NOS; Aicart-Ramos et al.,
2014; Sanchez-Ruiloba et al., 2014). In endothelial cells, VEGF
activation of PKD promotes vasodilation and angiogenesis via
S1179 phosphorylation, and activation, of eNOS. Numerous
signaling cascades and kinases target this regulatory site to boost
NO production, including Akt. The importance of PKD as a
regulatory kinase of eNOS and vascular tone was confirmed
in vivo, where inhibition of PKD dramatically reduced VEGF-
induced dilation of the carotid artery. Given its role in control
of cell proliferation, migration and angiogenic gene expression
(Liu et al., 2014; Ren, 2016), PKD signaling is seen as a key driver
of angiogenesis with interesting therapeutic possibilities. Several
studies have already shown pan-KD inhibition is beneficial in
cancer models [where both the tumor cells and angiogenesis
are targeted (Lavalle et al., 2010; Borges et al., 2015; Tandon
et al., 2015)]. However, given the plethora of signaling cues
that modulate angiogenesis in physiological and pathological
conditions, the precise role of PKD isoforms in these processes
should be worked out.
Neurohormonal Regulation of Nuclear
Signaling
The role of PKD in transcriptional regulation is well-
documented. PKD is involved in the regulation of several
transcription factors such as the activating enhancer binding
protein-2 (AP2; Kondo et al., 2011), T-cell factor (TCF; via beta
catenin; Jaggi et al., 2008), Snail1 (Eiseler et al., 2012), cAMP-
response element binding protein (CREB; Johannessen et al.,
2007; Ozgen et al., 2008), myocyte enhancer factor2 (MEF2;
Vega et al., 2004) and NFκB (nuclear factor κ-light-chain-
enhancer of activated B-cells; Holden et al., 2008). However,
only CREB and MEF2 regulation have been confirmed in the
heart. Here activation of PKD by Gq leads to CREB serine
133 phosphorylation and the induction of CRE-responsive
genes such as Bcl-2 contributing to cell survival (Ozgen et al.,
2008). Low levels of oxidative stress also promote CREB
phosphorylation, but this is associated with decreased CREB
abundance and no change CREB target gene transcription
(Ozgen et al., 2009). The importance of PKD-dependent
CREB phosphorylation in cardiac remodeling processes is still
unclear.
Protein Kinase D also influences gene expression by
modulating the epigenetic machinery, specifically the
transcriptional repressors class II HDACs. The Olson and
McKinsey labs firmly established PKD isoforms as HDAC
kinases (McKinsey and Olson, 2005). Following activation
and translocation to the nucleus, PKD associates with and
phosphorylates the 14-3-3 binding sites on the HDAC protein.
This unmasks a nuclear export sequence on HDAC, culminating
in crm1-dependent nuclear export of the HDAC-chaperone
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protein complex (McKinsey et al., 2001). The release of class II
HDACs from MEF2 allows for histone acetyltransferases (HATs)
to associate with MEF2 inducing chromatin relaxation and
transcriptional activation of fetal cardiac genes. PKD regulation
of HDACs exemplifies an emerging theme in PKD regulation
of its substrates: PKD target phosphorylation alters association
with 14-3-3 chaperone proteins and consequently intracellular
location of its substrates.
In contrast to CaMKII, each PKD isoforms can phosphorylate
all of the class IIa HDACs (HDAC4, 5, 7, and 9) but their
functional redundancy is not fully addressed and may
be signal-dependent (Ellwanger and Hausser, 2013). In B
lymphocytes, disruption of both PKD1 and 3 was required to
block HDAC7 phosphorylation in antigen receptor signaling
(Matthews et al., 2006). In the PKD1 cKO mice, fetal gene
activation and stress-induced hypertrophy is blunted,
suggesting that neither PKD2 and PKD3, nor CaMKII
can fully compensate for the loss of PKD1 (Fielitz et al.,
2008).
A number of regulatory interactions for PKD-HDAC signaling
axis have also been identified. Disruption of the small heat
shock protein 20 (hsp20)-PKD interaction, which chaperones
nuclear translocation of PKD1, inhibited nuclear import of
PKD and β-AR induced hypertrophy (Sin et al., 2015). In
microvascular endothelial cells, PKD1/HDAC7 signaling to
FoxO1 initiates proangiogenic and proarteriogenic transcription
by repression of CD36 transcription (Ren et al., 2016). Four-
and-a-half LIM domain proteins (FHL) 1 and 2, while not
actual PKD targets, were identified as novel PKD binding
partners that differentially facilitate neurohormonal activation
of PKD (FHL1 for ET, and FHL2 for both ET and α1-AR
agonists). Curiously, PKD regulation by FHL proteins affected
HDAC5 phosphorylation but not MEF2 activation (Stathopoulou
et al., 2014). Graeme Carnegie demonstrated that the AKAP-
Lbc (AKAP13) scaffold protein facilitates hypertrophic PKD-
HDAC signaling (Carnegie et al., 2008). This scaffolding protein,
located at the nuclear envelope and cytoskeleton, nucleates
PKCα, PKCη, PKA, and PKD, and promotes Rho activation
(Carnegie et al., 2004). Gene-trap mice expressing an AKAP-
Lbc variant that abolishes the PKD interaction (AKAP-Lbc-
1PKD) exhibited blunted cardiac hypertrophy in response
to Ang/PE treatment or pressure overload (Taglieri et al.,
2014; Johnson et al., 2015), in agreement with the PKD1cKO
mice. Unlike the PKD1cKO mice, the AKAP-Lbc-1PKD mice
had greater collagen deposition and displayed an accelerated
progression to cardiac dysfunction. This study further highlights
the compartmentalization aspect of PKD signaling and suggests
a critical in vivo role for AKAP-Lbc-anchored PKD signaling
in compensatory hypertrophy development. In contrast, the
Smrcka group proposes that the perinuclear mAKAP-PLCε
complex, which generates DAG from PI4P in the Golgi
apparatus in close proximity to the nuclear envelope, is the
crucial scaffold complex to regulate activation of nuclear PKD
and hypertrophic signaling pathways (Zhang et al., 2013).
The discordant result might be explained by signal-specific
pathways but both groups included ET as stimulus in their
study.
Neurohormonal Regulation of
Sarcomeric Signaling
Besides the long term nuclear effects, PKD signaling may
also contribute to excitation-contraction coupling regulation via
effects on sarcomeric proteins. A number of PKD substrates
have been identified thus far: the titin-cap protein telethonin
(Candasamy et al., 2014), troponin I (TnI; Cuello et al., 2007) and
Myosin Binding Protein c (MyBPc; Bardswell et al., 2010; Dirkx
et al., 2012a). Upon phosphorylation of TnI at Serine 22 and 23,
the sites also targeted by PKA, myofilament Ca2+ sensitivity is
reduced. Phosphorylation of MyBPc at Serine 302 and Serine 315
accelerates crossbridge cycling kinetics and increases maximal
Ca2+-activated contraction tension.
Force generation was not modulated by the coordinated
phosphorylation of TnI and MyBPc. Instead, active PKD can
affect force generation by increasing Ca2+ current via increased
surface expression of LTCCs. Paradoxically, α1-AR stimulation
with PE, elicits a triphasic response in both the left ventricle
(LV) and right ventricle (RV), but an overall positive inotropic
response in LV trabeculae and an overall negative inotropic
response in RV trabeculae (Wang et al., 2006). The overall
response of each ventricle does not correspond to the response
of individual myocytes, however, as α1-AR signaling causes both
a positive and negative inotropic effect in individual myocytes of
both ventricles that is independent of which α1-AR subtype is
stimulated (Chu et al., 2013). In what is likely a compensatory
mechanism, heart failure shifts the overall negative response to
PE in the RV to a positive one (Wang et al., 2010). Although
PKD is a key target of α1-AR signaling it is unknown whether α1-
adrenergic-PKD signaling is involved in either the heterogeneous
inotropic response of individual myocytes or the switch of
inotropy during HF.
Despite a well-established nuclear translocation effect from
the membrane to the nucleus, the spatiotemporal dynamics of
PKD at its sarcomeric targets has not been assessed. It is unclear
whether the active PKD that phosphorylates TnI and MyBPc
originates from the same pool that is destined for the nucleus,
or whether there is a separate scaffolded pool of PKD available to
respond locally within the sarcomeres.
OXIDATIVE STRESS-DEPENDENT PKD
SIGNALING
Evanescent reactive oxygen species (ROS) are continuously
produced by metabolic and cellular processes and may
accumulate with ischemic injury or upon various pathological
insults, determining whether ROS act as modulators of signal
transduction pathways and physiological processes or as
mediators of cellular injury. Extensive data have implicated
ROS in the development and progression of cardiovascular
disease, diabetes, cancer and neurodegenerative disorders.
Not so surprisingly, PKD is also activated by oxidative stress.
Downstream of PKD activation, three pathways were shown
to impact cell survival: via NFκB, RhoA, and c-Jun N-terminal
kinase (JNK) (Figure 2) (Storz and Toker, 2003a; Waldron
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et al., 2004; Zhang et al., 2005; Xiang et al., 2011). To promote
these oxidative stress responses, PKD acts in the nucleus and
mitochondria.
Oxidative Stress Regulation of Nuclear
signaling
In endothelial cells, PKD1 was found to be a critical mediator of
H2O2- but not TNF-induced apoptosis signal-regulating kinase
1 (ASK1) activation of JNK (Waldron et al., 2004; Zhang et al.,
2005). Here H2O2 triggered PKD activation and translocation
from the membrane to the perinuclear region, where it associated
with ASK1, before progressing to the nucleus. The ASK1-PKD1
interaction (via the PKD PH domain) was critically dependent
on 14-3-3 binding to PKD at two pairs of phosphorylated serines
(205/208 and 219/223). The H2O2 –induced ASK-JNK activation
and endothelial cell apoptosis was blocked with PKD inhibition
or siRNA knockdown. Whether ASK1 is also modulated by PKD
in cardiomyocytes or whether PKD1 regulation of ASK1 activity
is via direct phosphorylation (as shown for CaMKII) is still
unknown.
Oxidative Stress Regulation of
Mitochondria to Nucleus Signaling
The Storz group identified a pathway where PKD activation
by mitochondrial ROS led to induction of antioxidative genes
through activation of NFκB. In HeLa cells, mitochondrial
oxidative stress promoted local DAG production by
phospholipase D1 evoking PKD translocation to the
mitochondria (Cowell et al., 2009). PKD activation at the
mitochondria was dependent upon the tyrosine kinases
c-Abl and Src (Storz et al., 2003). c-Abl phosphorylation
of Tyrosine 463 within the PKD PH domain led to loss of
autoinhibition and Src phosphorylation of PKD Tyrosine 95.
These phosphotyrosines create a docking site for PKCδ via its
C2 domain and subsequently phosphorylation of Serine 744/748
in the activation loop. PKCδ recognizes this phosphorylated
tyrosine and associates with PKD resulting in phosphorylation
at Serines 744 and 748 (Storz et al., 2004). Active PKD then
phosphorylates inhibitor of NFκB kinase β (IKKβ) at Serine
181, which allows for IκBα degradation and NFκB activation
(Storz and Toker, 2003b). In the nucleus NFκB promotes
SOD2 gene transcription which encodes the mitochondrial
protein manganese depend superoxide dismutase (MnSOD;
Storz et al., 2005). The subsequent detoxification of ROS
resulted in increased cell survival but perturbation of any
components in this pathway led to increased cell death. It is
not clear whether this pathway operates in cardiac myocytes.
It should also be noted that growth factor-dependent PKD1
signaling cascades do not activate NFκB nor induce MnSOD,
underscoring the impact of contextual cues and specific post-
translational modifications of PKD1 on achieving unique cellular
outcomes.
Protein Kinase D1-mediated protection from oxidative stress
may also be mediated via RhoA signaling (Xiang et al.,
2013a). During ischemia-reperfusion injury cardiomyocytes
release the cardioprotectant sphingosine 1-phosphate (S1P;
Vessey et al., 2009). The signaling cascade initiated by S1P
via its Gα12/13-coupled receptor, produce guanine nucleotide
exchange factors for RhoA activation which in turn activates
PLCε (Wing et al., 2003; Xiang et al., 2013b). The surge
in DAG, activates PKD1 which then phosphorylates and
inhibits Slingshot 1L (SSH1L), a phosphatase/activator of
cofilin (actin depolymerization factor). S1P thus attenuates
cofilin translocation to mitochondria and association with the
pro-apoptotic BAX (bcl-2-associated X protein), preserving
mitochondrial integrity and cell survival in the face of
oxidative stress (Klamt et al., 2009). In mice with genetic
deletion of PKD1 or PLCε, S1P-mediated cardioprotection
against ischemia/reperfusion injury was reduced (Xiang et al.,
2013b). The PKD-slinghot-cofilin signaling axis is one of
many PKD-mediated pathways regulating actin dynamics
described thus far (Olayioye et al., 2013). Determining if
PKD also fulfills this role in cardiac cell types may shed
light on cytoskeletal and actin rearrangement seen with heart
failure.
METABOLIC STRESS-DEPENDENT PKD
SIGNALING
Investigation of PKD signaling in pancreatic and muscle tissue is
a developing field that can potentially reveal novel molecules and
pathways that regulate metabolism and diabetes development.
PKD signaling has already been implicated in the regulation of
energy substrate utilization and insulin secretion. Intriguingly
the PRKD1 gene locus has also been associated with increased
body mass index (Speliotes et al., 2010; Comuzzie et al.,
2012; Graff et al., 2013; Shaheen et al., 2015; Sifrim et al.,
2016). Graff et al. (2013) further found a stronger impact
during adolescence than in older adults which could reflect
PKD expression decline in adulthood (as shown in rodent
hearts; Haworth et al., 2000; Vega et al., 2004; Guo et al.,
2011). Although obesity is the best predictor for type 2
diabetes development the few studies examining PKD function
in diabetic models provided conflicting results as both PKD
overexpression and inhibition were linked to improved cardiac
function.
Metabolic Stress Regulation of Golgi to
Membrane Signaling
In pancreatic β-cells, PKD1 is essential for glucose-stimulated
insulin secretion signaling downstream of the long-chain fatty
acid (LCFA) receptor GPR40 (Ferdaoussi et al., 2012). In
these cells PKD activity is negatively controlled by MAPKp38δ
phosphorylation (at Serines 397/401). Accordingly, p38δ KO
mice displayed high constitutive PKD activity and were protected
against high-fat-feeding induced insulin resistance and oxidative
stress–induced βcell failure (Sumara et al., 2009).
In the heart, PKD is crucial for contraction-induced
translocation of the glucose transporter type 4 (GLUT4),
an essential step to stimulate cardiac glucose uptake during
increased energy demand (Luiken et al., 2008). The underlying
mechanism is not a direct effect of ATP/AMP levels, as
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with AMP-activated kinase (AMPK), but rather a result of
contraction-induced ROS production, association of death-
activated protein kinase (DAPK) and subsequent PKD
activation (Dirkx et al., 2012b). AMPK represents the other
obligatory signaling branch regulating GLUT4 translocation
in cardiomyocytes, but unlike PKD, AMPK also mediates
increased CD36 membrane translocation, allowing for LCFA
to enter the cell (Dirkx et al., 2012b). Indeed, PKD1 cKO
myocytes, despite having intact AMPK levels, do not increase
their glucose uptake with pacing and their LCFA uptake is
enhanced (Dirkx et al., 2014). Conversely, mice expressing
constitutively active PKD1 (caPKD1) have 1.5 times the level
of basal glucose uptake and a more pronounced increase in
uptake in response to pacing than WT myocytes (Dirkx et al.,
2014). Distinct roles for PKD and AMPK are also seen in rat
cardiomyocytes with low glucose uptake induced by high insulin
or high palmitate culture conditions. Either PKD or AMPK
overexpression prevents loss of insulin-stimulated glucose
uptake. But while overexpression of PKD in cardiomyocytes
prevents lipid loading, AMPK overexpression promotes
retention of insulin-stimulated Akt signaling (Steinbusch et al.,
2013). Given its independence from the insulin signaling
axis, the PKD signaling pathway represents a strategic option
to increase glucose uptake in the insulin-resistant diabetic
heart.
Conversely, PKD also regulates cardiomyocyte lipoprotein
lipase (LPL) secretion, which hydrolyzes lipoproteins at the
vascular lumen (Kim et al., 2008). In diabetes, the observed
increase in LPL facilitates the switch to the disproportionate use
of fatty acids (FA) which ultimately leads to excessive cardiac
lipid accumulation and dysfunction (Wang and Rodrigues, 2015).
The action of PKD1 to regulate LPL-mediated triglyceride
accumulation was discovered in mice treated with diazoxide
to decrease insulin secretion and cause hyperglycemia. The
mechanism relied on heat shock protein 25 dissociation from
PKCδ, permitting PKCδ association with and activation of PKD.
Active PKD then promoted vesicular trafficking and release
of LPL. A subsequent study recapitulated these findings in
rats using low dose streptozotocin (STZ) to induce moderate
hypoinsulinemia (Kim et al., 2009). Whereas in rats with
severe hypoinsulinemia induced by a higher dose of STZ, LPL
activity at the vascular lumen was diminished. The loss of
LPL stimulation was attributed to caspase-dependent cleavage
of PKD (resulting in a modest increase in basal activity of
the kinase, but severe limitation of its maximal activation).
These observations contrast with the finding that cardiac
lipid overload and insulin resistance are largely prevented
in caPKD mice fed a high fed diet (Dirkx et al., 2014).
Clearly further investigation is needed to clarify the beneficial
and pathogenic roles of PKD in regulating energy substrate
utilization.
Metabolic Stress Regulation of Nuclear
Signaling
Several groups have performed proof-of-concept studies
targeting PKD in diabetic models. Some groups have targeted
PKD-mediated cardiac remodeling in diabetic cardiomyopathy,
while others have attempted to capitalize on PKD modulation
of fuel selection. Using the early stage type 2 diabetes model
db/db mice, which have a point mutation in one of the leptin
receptor genes, administration of the pan-PKD inhibitor
CID755673 for 2 weeks effectively inhibited PKD isoforms,
suppressed the gene expression signature of PKD activation and
enhanced diastolic and systolic function as well as reduced heart
weight. The improvement in cardiac indices was independent
of effects on glucose homeostasis, insulin action and body
composition (Venardos et al., 2015). Liu et al. likewise found that
the observed cardiac fibrosis, apoptosis, diastolic dysfunction
and ER stress were all related to PKD activation in a rat
diabetic model achieved by a combined low dose STZ and high
fat diet (4 weeks). Irbertesan treatment ameliorated cardiac
remodeling and function in this model, which was attributed to
inhibition of PKD activation and ER stress function (Liu et al.,
2015).
A third model, mice on a chronic (8 weeks) high fat diet,
displayed the characteristic insulin resistance, cardiac switch
to LCFA and lipid deposition, and LV concentric hypertrophy
but also reduced PKD expression and activity levels (Dirkx
et al., 2014). Interestingly, applying the high fat diet to caPKD1
mice rescued their baseline dilated cardiomyopathy phenotype
(without inducing hypertrophy) and also prevented cardiac
lipid overload and insulin resistance. The only two mutual
responses to high fat diet of WT and caPKD mice were
reduced protein levels of PKD and decreased levels of HDAC5
phosphorylation. Of note, despite the decreased PKD expression,
PKD activity levels were unchanged, suggesting that not just
the expression but also the location and/or substrate of PKD
is altered by metabolic stress. Some of these conflicting reports
likely reflect variations in the animal models and our poor
understanding of the temporal and complex role of PKD
signaling in metabolism. There is a tendency to oversimplify
the mechanistic basis of PKD effects to the context of single
downstream targets (e.g., cardiac remodeling to the HDAC5-
Mef2 axis), which is clearly not the only mode of action.
Much remains to be learned about the precise regulation
and effectors of PKD signaling in response to metabolic
stress.
CONCLUDING REMARKS
The preceding studies convincingly implicate PKD in the
pathogenesis of multiple cardiovascular risk factors and the
subsequent cardiovascular disease, but are just the tip of the
iceberg. We are still far from understanding the intricacies of
PKD signaling especially in the context of complex disease
pathways. Many questions remain unanswered regarding the
specific beneficial and pathogenic roles of PKD and the
role of specific PKD isoforms therein. Tissue- and isoform-
specific KO mice, as well as the development of isoform-
specific PKD inhibitors should provide important breakthroughs.
Another critical challenge is the vexing state of affairs regarding
straightforward analysis of PKD activation state. Proteomic
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approaches identifying the relevant regulatory post-translational
modifications and interactions would provide key insight into
PKD signaling specificity and regulation. This approach could
also guide the identification and verification of PKD effector
targets in cardiovascular cells. Finally, PKD represents an enticing
therapeutic target for a number of pathologies including cancer.
Given the already apparent complexities of the functions and
interactions of PKD isoforms, it is unlikely that a “one size fits all”
PKD inhibitor will be a viable therapeutic strategy. Any successful
strategy will have to minimize undesirable off-target effects but
also adverse on-target effects in other tissues.
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